- Home
- VANI vs IMA Comparison
VANI vs IMA Comparison
Compare VANI & IMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VANI | IMA |
|---|---|---|
| Founded | 1998 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 81.2M | 65.4M |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | VANI | IMA |
|---|---|---|
| Price | $1.28 | $5.81 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 2 |
| Target Price | $4.00 | ★ $16.00 |
| AVG Volume (30 Days) | ★ 192.4K | 63.4K |
| Earning Date | 11-13-2025 | 02-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $800,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.91 | $5.75 |
| 52 Week High | $1.92 | $18.00 |
Technical Indicators
Market Signals| Indicator | VANI | IMA |
|---|---|---|
| Relative Strength Index (RSI) | 39.16 | N/A |
| Support Level | $1.36 | N/A |
| Resistance Level | $1.46 | N/A |
| Average True Range (ATR) | 0.09 | 0.00 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 6.67 | 0.00 |
Price Performance
Historical ComparisonAbout VANI Vivani Medical Inc. (DE)
Vivani Medical Inc is a preclinical-stage biopharmaceutical company. The company develops miniaturized, subdermal implants utilizing its proprietary NanoPortal technology to enable long-term, near-constant-rate delivery of a broad range of medicines to treat chronic diseases. It has two reporting segments, the Biopharm Division and the Neuromodulation Division. The Biopharm Division includes activities from NPM and Vivani Medical Australia Pty Ltd, and the Neurostimulation Division includes activities from Cortigent and its subsidiary in Switzerland.
About IMA ImageneBio Inc.
ImageneBio Inc is a clinical-stage biopharmaceutical company that develops differentiated therapies for immunological and inflammatory (I&I) diseases. The company is focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody, for the treatment of atopic dermatitis.